TrialInflammatory bowel diseases2025

Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study.

Miguel Regueiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.